Global cardiovascular clinical trials market to reach $7.69B by 2030 at 5.9% CAGR
The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.
How Is The Market Size Of The Cardiovascular Clinical Trials Market Expected To Change From 2026 To 2030?
The market size for cardiovascular clinical trials has demonstrated robust growth recently. This market is projected to expand from $5.72 billion in 2025 to reach $6.12 billion by 2026, exhibiting a compound annual growth rate (CAGR) of 7.0%. Historically, this expansion has been driven by factors such as the growing burden of cardiovascular diseases, the expansion of global clinical research activity, increasing regulatory approvals for novel therapies, the availability of established trial infrastructure, and the growth of multicenter studies.
The cardiovascular clinical trials market size is projected to experience robust expansion over the coming years. This market is anticipated to reach $7.7 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 5.9%. The expansion throughout the projected period can be ascribed to several factors, including the escalating demand for quicker trial execution, the growing adoption of AI-driven trial analytics, the broader implementation of remote patient engagement, an intensified focus on patient-centric trial designs, and increased investment in cardiovascular drug pipelines. Key trends expected during this forecast span encompass the wider uptake of decentralized trial models, an increase in the utilization of digital patient monitoring tools, greater integration of biomarkers into study design, the expansion of real-world evidence generation, and a heightened emphasis on adaptive trial designs.
Access Your Free Sample Report For In-Depth Market Analysis:
What Major Factors Are Driving The Cardiovascular Clinical Trials Market Forward?
The escalating occurrence of cardiovascular diseases is projected to fuel the expansion of the cardiovascular clinical trials market going forward. Cardiovascular disease encompasses a range of conditions impacting the heart and blood vessels, such as coronary artery disease, heart failure, and stroke. The rise in these diseases is linked to various elements, including inactive lifestyles, poor dietary habits, tobacco use, excess weight, elevated blood pressure, diabetes, and inherited predispositions. Cardiovascular clinical trials are instrumental in identifying and confirming novel medications capable of more efficiently addressing risk factors like hypertension, high cholesterol, and diabetes, which play a crucial role in CVD development. A case in point, data released in September 2024 by the Minnesota Department of Health, a US-based state health agency, indicated that about 30% of adults in Minnesota reported having high blood pressure in 2023, amounting to nearly 1.4 million individuals. Furthermore, in 2022, conditions related to hypertension served as the primary or contributing cause of death for 14,225 residents, accounting for almost 28% of all deaths within the state. Consequently, the increasing prevalence of cardiovascular diseases is propelling the growth of the cardiovascular clinical trials market.
Which Segment Classifications Are Used In The Cardiovascular Clinical Trials Market Segment Analysis?
The cardiovascular clinical trials market covered in this report is segmented –
1) By Phase: Phase I, Phase II, Phase III, Phase IV
2) By Study Design: Interventional, Observational, Expanded Access
3) By Indication: Acute Coronary Syndrome, Coronary Artery Disease, Ischemic Heart Disease, Pulmonary Arterial Hypertension, Stroke, Cardiac Arrhythmias, Heart Failure, Other Indications
Subsegments:
1) By Phase I: First-in-Human Trials, Dose Escalation Studies, Safety and Tolerability Studies, Pharmacokinetics And Pharmacodynamics Studies
2) By Phase II: Efficacy Studies, Optimal Dosage And Administration Route Studies, Early Safety And Efficacy Trials, Biomarker Development Trials
3) By Phase III: Large-Scale Efficacy Trials, Randomized Controlled Trials (RCTs), Long-Term Safety And Efficacy Studies, Multicenter Trials
4) By Phase IV: Post-Marketing Surveillance, Long-Term Safety Studies, Real-World Evidence (RWE) Studies, Comparative Effectiveness Research
Which Trends Are Impacting The Progress Of The Cardiovascular Clinical Trials Market?
Major companies active within the cardiovascular clinical trials market are prioritizing strategic alliances, such as collaborations with contract research organizations (CROs), to broaden their distribution networks and engage a wider client base. These CRO partnerships are vital within the clinical research sector, involving joint efforts among various companies to deliver specialized services and support for diverse aspects of clinical trials and research endeavors. For instance, in September 2023, Cereno Scientific AB, a biopharmaceutical firm based in Sweden, partnered with Clinical Trial Consultants (CTC), a full-service CRO also located in Sweden, specializing in clinical conduct. This collaboration is for a Phase I study concerning CS014, a histone deacetylase inhibitor designed to prevent arterial and venous thrombosis. CTC will further aid in Phase I preparation stages, including the development of the study protocol and the clinical trial application process for the study, which is planned for Sweden. This initial human Phase I trial is anticipated to commence in the first half of 2024, marking a significant step forward in cardiovascular health research.
Which Firms Are Contributing To The Cardiovascular Clinical Trials Market Ecosystem?
Major companies operating in the cardiovascular clinical trials market are Pfizer Inc., Johnson & Johnson, AstraZeneca PLC, Novartis AG, Eli Lilly and Company, Amgen Inc., Boehringer Ingelheim International GmbH, Merck & Co Inc., Sanofi, Baxter International Inc., IQVIA Holdings Inc., ICON plc, Syneos Health Inc., PPD Inc., Medpace Holdings Inc., Worldwide Clinical Trials, SGS SA, Charles River Laboratories International Inc., WuXi AppTec Co Ltd, Gilead Sciences Inc.
Get The Full Cardiovascular Clinical Trials Market Report:
Which Region Holds The Highest Market Share In The Cardiovascular Clinical Trials Market?
North America was the largest region in the cardiovascular clinical trials market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the cardiovascular clinical trials market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request A Customized Cardiovascular Clinical Trials Market Report For Competitive Insights:
Browse Through More Reports Similar to the Global Cardiovascular Clinical Trials Market 2026, By The Business Research Company
Cardiovascular Digital Solutions Market Report 2026
Cardiovascular Drugs Market Report 2026
https://www.thebusinessresearchcompany.com/report/cardiovascular-drugs-global-market-report
Cardiovascular Health Supplements Market Report 2026
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
